Drug affinity and targeted delivery: double functionalization of silk spheres for controlled doxorubicin delivery into Her2-positive cancer cells

被引：0
|
作者：
Kamil Kucharczyk
Anna Florczak
Tomasz Deptuch
Karolina Penderecka
Katarzyna Jastrzebska
Andrzej Mackiewicz
Hanna Dams-Kozlowska
机构：
[1] Poznan University of Medical Sciences,Chair of Medical Biotechnology
[2] Greater Poland Cancer Centre,Department of Diagnostics and Cancer Immunology
来源：
Journal of Nanobiotechnology | / 18卷
关键词：
Silk; Genetic engineering; Spheres; Drug carrier; Doxorubicin; Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Cancer stem cells and strategies for targeted drug delivery
    Jin Cao
    Shubhmita Bhatnagar
    Jiawei Wang
    Xueyong Qi
    Swayam Prabha
    Jayanth Panyam
    Drug Delivery and Translational Research, 2021, 11 : 1779 - 1805
  • [42] AAV-Mediated Riboswitch-Controlled Delivery of Anti-HER2 Antibody Suppresses HER2-Positive Tumorigenesis
    Wang, George
    Zhong, Zhaojing
    Oh, Jae Gyun
    Waksal, Samuel
    Forbes, Alexandria
    Guo, Xuecui
    MOLECULAR THERAPY, 2023, 31 (04) : 661 - 661
  • [43] A silk platform that enables electrophysiology and targeted drug delivery in brain astroglial cells
    Benfenati, Valentina
    Toffanin, Stefano
    Capelli, Raffaella
    Camassa, Laura M. A.
    Ferroni, Stefano
    Kaplan, David L.
    Omenetto, Fiorenzo G.
    Muccini, Michele
    Zamboni, Roberto
    BIOMATERIALS, 2010, 31 (31) : 7883 - 7891
  • [44] Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
    Schramm, Amelie
    De Gregorio, Nikolaus
    Widschwendter, Peter
    Fink, Visnja
    Huober, Jens
    BREAST CARE, 2015, 10 (03) : 173 - 178
  • [45] Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
    Yoshikawa, Ayumu
    Nakamura, Yoshiaki
    CANCERS, 2023, 15 (01)
  • [46] The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
    Bragina, Olga D.
    Deyev, Sergei M.
    Chernov, Vladimir, I
    Tolmachev, Vladimir M.
    ACTA NATURAE, 2022, 14 (02): : 4 - 15
  • [47] Exploring Targeted Therapy for HER2-Positive Metastatic Breast Cancer
    Terrie, Yvette C.
    US PHARMACIST, 2022, 47 (10) : 34 - 39
  • [48] Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer
    Veeraraghavan, Jamunarani
    Liao, Fu-Tien
    Qin, Lanfang
    Gordon, Tia
    Raghavan, Alekya
    Sabotta, Caroline
    Kaplan, Rachel
    Gutierrez, Carolina
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    CANCER RESEARCH, 2024, 84 (03)
  • [49] Controlled Formulation of Doxorubicin-Polylactide Nanoconjugates for Cancer Drug Delivery
    Tong, Rong
    Tang, Li
    Yala, Linda
    Cheng, Jianjun
    2009 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-20, 2009, : 2400 - 2402
  • [50] Novel HER2-targeted therapies for HER2-positive metastatic breast cancer
    Kunte, Siddharth
    Abraham, Jame
    Montero, Alberto J.
    CANCER, 2020, 126 (19) : 4278 - 4288
12345